Investigators From The US Oncology Network, US Oncology Research and McKesson Present More Than 60 Research Abstracts During the 2019 American Society of Clinical Oncology Annual Meeting

Important and growing role of community oncologists in clinical research
and evidence generation across multiple cancer types

IRVING, Texas–(BUSINESS WIRE)–Investigators from McKesson,
The
US Oncology Network (The Network) and US
Oncology Research will showcase detailed findings from more than 60
studies during the 55th Annual Meeting of the American Society of
Clinical Oncology (ASCO).
The meeting, being held in Chicago from May 31 to June 4, 2019, will
bring together more than 32,000 oncology professionals from around the
globe.

“ASCO continues to serve as a meaningful platform for community
oncologists to share learnings and real-world evidence that advance
therapies and care practices to foster the utmost care for oncology
patients,” said Michael Seiden, MD, PhD, president, The US Oncology
Network. “As therapies continue to improve and become more personalized
to the individual’s particular cancer, staying engaged in cutting-edge
clinical trials and sharing our findings with forward-thinking
colleagues in the oncology community help oncologists and researchers in
The Network contribute in meaningful ways in the fight against cancer.”

Key study presentations during this year’s conference will include
research on sarcoma, non-small cell metastatic lung cancer, hematologic
malignancies (such as leukemia, myelodysplastic syndromes and
allotransplant), developmental immunotherapy and tumor immunobiology,
non-Hodgkin lymphoma, developmental therapeutics and tumor biology and
genitourinary (non-prostate) cancer. Some of these studies utilized
high-quality real-world data captured from iKnowMed℠,
McKesson’s oncology practice electronic health record (EHR) system that
was named
the top-ranked EHR platform for oncologists and
hematologists for the eighth year in a row by Black
Book™ Research. Through McKesson’s Data,
Evidence and Insights business, this rich, regulatory-grade data is
leveraged to support biopharmaceutical real-world evidence needs.

“The increased role of real-world evidence is ever important in
improving patient outcomes for individuals battling cancer,” said
Nicholas Robert, MD, medical director of Data, Evidence & Insights,
McKesson Life Sciences. “Furthermore, regulatory agencies now consider
these data sets as a part of a bigger picture when evaluating a
therapeutic filing, especially in areas with unmet needs.”

Additionally, at the event, Debra
Patt, MD, MPH, MBA, of Texas
Oncology, a practice in The US Oncology Network, will officially be
recognized with her designation of Fellow of the American Society of
Clinical Oncology (FASCO). The designation honors the most active ASCO
volunteers. Dr. Patt is a long-standing member of the community
oncologist community with more than 20 years of experience. She also
serves as editor-in-chief of JCO Clinical Cancer Informatics and
is a member of ASCO’s Nominating Committee, White and Brown Bagging
Committee, Clinical Practice Committee (CPC) Physician Compensation
Workgroup, MACRA Speakers Group and CPC Payment Reform Implementation
Workgroup.

“From harnessing data- and evidence-driven insights to breakthrough
genetics-based scientific research, the pace of advancement in cancer
treatment is more robust now than at any time in my career,” said Dr.
Patt. “New, more personalized treatments are revolutionizing oncology
and delivering profound benefits to patients. We have witnessed the
first cancer therapies approved by the FDA that have included real-world
evidence. ASCO provides us with a glimpse of the future and the promise
it holds for our patients. I’m honored to be named a recognized Fellow
and to be able to bring real-world perspectives from community-based
oncology to this outstanding organization.”

The full schedule of affiliated data presentations, including location
information, can be found here.
For more information or to be put in touch with a trial investigator,
contact Claire Crye at 281.825.9927 or Edie DeVine at 209.814.9564.
Please visit Booth #4089 in the ASCO Exhibit Hall.

About US Oncology Research

US
Oncology Research draws from a network of more than 1,000
experienced investigators and dedicated clinical staff who specialize in
oncology clinical trials. US Oncology Research serves approximately 60
research sites and more than 155 locations, managing about 300 active
trials at any given time. For the past 20 years, physicians in the
research network have enrolled more than 77,000 patients in over 1,600
trials and have played a role in more than 85 FDA-approved cancer
therapies, approximately one-third of all cancer therapies approved by
the FDA to date. US Oncology Research is supported by McKesson
Corporation.

About The US Oncology Network

Every day, The
US Oncology Network (The Network) helps more than 1,200 independent
physicians deliver value-based, integrated care to patients — close to
home. Through The Network, these independent doctors come together to
form a community of shared expertise and resources dedicated to
advancing local cancer care and to delivering better patient outcomes.
The Network provides practices with access to coordinated resources,
best business practices, and the experience, infrastructure and support
of McKesson
Corporation. This collaboration allows the providers in The Network
to focus on the health of their patients, while McKesson focuses on the
health of their practices. The Network is committed to the success of
independent practices, everywhere.

About McKesson Corporation

McKesson Corporation, currently ranked 7th on the FORTUNE 500, is a
global leader in healthcare supply chain management solutions, retail
pharmacy, healthcare technology, community oncology and specialty care.
McKesson partners with life sciences companies, manufacturers,
providers, pharmacies, governments and other healthcare organizations to
help provide the right medicines, medical products and healthcare
services to the right patients at the right time, safely and
cost-effectively. United by our ICARE shared principles, our employees
work every day to innovate and deliver opportunities to improve patient
care in every setting — one product, one partner, one patient at a time.
McKesson has been named a “Most
Admired Company” in the healthcare wholesaler category by FORTUNE, a
“Best
Place to Work” by the Human Rights Campaign Foundation, and a top military-friendly
company by Military Friendly. For more information, visit www.mckesson.com.

Contacts

McKesson
Claire Crye, Public Relations
T 281.825.9927 claire.crye@mckesson.com